Norris Medicines has informed that the Board of Directors at their Meeting held on 13th February, 2023, has approved the Unaudited financial results for the Quarter and nine months ended 31st December 2022. As per Regulation 33 of Listing Regulations, the Financial Results and Limited Review Report are enclosed for records. The Meeting of the Board of Directors concluded at 12:30 PM.
The above information is a part of company’s filings submitted to BSE.